Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
Not a peptide but a small molecule: a direct switch for AMPK — the cell's "fuel gauge", which metformin activates only indirectly. Taken by mouth; studied in fatty liver disease.
Size: 10 mg
No published analyses yet.
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Lower regimen | 250 mg once daily, oral | Starting dose |
| Split regimen | 250 mg twice daily (500 mg/day) | Increase if needed |
| Main studied regimen | 500 mg once daily | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | Patients with nonalcoholic fatty liver disease, oral PXL770, assessed at week 12 | The most frequent treatment-emergent event in the abstract; no percentage given, and complete safety tables were not read | [1] |
| Treatment-emergent adverse events overall | The same patients, all trial arms | Occurred in all arms, including placebo; dose groups were not pooled | [1] |
FAQ
Find answers to questions about PXL770 and related materials.
PXL770 is not a peptide but a synthetic small molecule from the French company Poxel, made to be taken by mouth. Its target is AMPK, the cell’s "fuel gauge" enzyme: when energy runs low, AMPK switches metabolism from storing to spending — braking fat synthesis and switching on fat oxidation.
Source / documentationThe key difference: most known AMPK activators (metformin, AICAR) act indirectly — they change the cell’s energy state and the enzyme reacts to a secondary signal. PXL770 switches AMPK on directly, so its profile is cleaner and more predictable.
Source / documentationAbove all in fatty liver disease: phase 2a (the STAMP-NAFLD study) looked at exactly this direction, since AMPK is the central switch of fat metabolism. Details are in the PXL770 monograph in our wiki.
Source / documentationOrally, as capsules or tablets. In phase 2a the regimens were 250 mg once a day or 250 mg twice a day. Schedules are in the dosing guide on this page.
Source / documentationThere is no complete safety profile for use outside studies, so an honest exhaustive list cannot be compiled. A full review of the known data is in the PXL770 monograph in our wiki.
Source / documentationStore in a dry, dark place at a low temperature. Details are in the PXL770 guide on this page.
Source / documentationYou can buy PXL770 right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. The product ships with the certificate of analysis (COA) for its exact batch.
Source / documentationShare your experience
No reviews yet. Tell others what you think of this product.
PXL770 is not a peptide but a synthetic small molecule from the French company Poxel, made to be taken by mouth. Its target is AMPK, the cell's "fuel gauge" enzyme: when energy runs low, AMPK switches metabolism from storing to spending — braking fat synthesis and switching on fat oxidation.
The key difference: most known AMPK activators (metformin, AICAR) act indirectly — they change the cell's energy state and the enzyme reacts to a secondary signal. PXL770 switches AMPK on directly, so its profile is cleaner and more predictable. Details are in the PXL770 monograph.
How it is used: orally, as capsules or tablets. In phase 2a (the STAMP-NAFLD study in fatty liver disease) the regimens were 250 mg once a day or 250 mg twice a day. Schedules are in the dosing guide; the full line is in the AMPK activators category, where its peptide neighbour is MOTS-c.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Store in a dry, dark place at a low temperature.